Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nitric oxide inhalation - Vero Biotech

Drug Profile

Nitric oxide inhalation - Vero Biotech

Alternative Names: GeNOsyl; GENOSYL (nitric oxide) gas; GENOSYL Delivery System; GENOSYL® inhaled nitric oxide ; GENOSYL®DS; inhaled Nitric oxide - VERO Biotech; iNO - VERO Biotech; MVG-2000

Latest Information Update: 30 Mar 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GeNO LLC
  • Developer Vero Biotech
  • Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antifibrotics; Antifungals; Antihypertensives; Antivirals; Cardiovascular therapies; Diagnostic agents; Free radicals; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Guanylate cyclase stimulants; Nitric oxide donors; Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypoxic respiratory failure
  • New Molecular Entity No

Highest Development Phases

  • Registered Hypoxic respiratory failure
  • Phase II Pulmonary arterial hypertension
  • Clinical Phase Unknown Cardiovascular disorders

Most Recent Events

  • 26 Mar 2020 Clinical trials in Cardiovascular disorders (cardiopulmonary symptoms associated with COVID-2019 infections) in USA (Inhalation) before March 2020
  • 26 Mar 2020 US FDA approves nitric oxide inhalation for "expanded access emergency use" for the treatment of Cardiovascular disorders (cardiopulmonary symptoms associated with COVID-2019 infections) in USA
  • 20 Dec 2019 Registered for Hypoxic respiratory failure (In neonates) in USA (Inhalation)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top